Roflumilast acts as a specialized phosphodiesterase-4 inhibitor for chronic obstructive pulmonary disease management. It works intracellularly to decrease the activity of inflammatory cells, supporting clearer airways and improved respiratory function.
Roflumilast belongs to the class of phosphodiesterase-4 (PDE-4) inhibitors, a group of compounds that influence inflammatory pathways. Its chief therapeutic purpose is to reduce airway inflammation, making it a key component in certain respiratory treatments. As the active ingredient, roflumilast is present in medications marketed under the name “Roflumilast” and similar formulations.
Roflumilast is supplied mainly as oral tablets, though some regions also offer inhaled preparations. In Singapore, both generic versions and brand-named products list roflumilast as the sole active component. The dosage strength can vary between products, so patients should reference the specific labeling on their medication package.
The medication is typically considered for adult patients who continue to experience symptoms despite standard inhaled therapies.
Roflumilast blocks the activity of the PDE-4 enzyme, which normally breaks down cyclic AMP (cAMP) in immune cells. By inhibiting this enzyme, cAMP levels rise, leading to a reduction in the release of inflammatory mediators. The overall effect is a calmer airway environment, which can translate to fewer breathing difficulties and less mucus production.
These sensations are usually brief and may lessen as the body adjusts to the medication.
If any of these signs appear, immediate medical attention is advisable.
Roflumilast may alter the effects of certain drug classes, such as strong CYP3A4 inhibitors, and can intensify the impact of alcohol on the gastrointestinal system. For a complete list of potential interactions, refer to the detailed information provided with each specific medication.
The tablets should be stored at room temperature, away from moisture and direct sunlight. Treatment length differs: some patients use roflumilast for a limited period during an exacerbation, while others may remain on therapy for ongoing disease management. Variation in dosing and instructions can exist between the different roflumilast products available locally; therefore, the label on the individual package remains the primary source for usage guidance.
This article provides an educational overview of roflumilast as an active compound and does not constitute medical advice. Individual medicines containing roflumilast may differ in formulation, strength, and directions for use. The information herein is offered without liability for clinical application. Readers are encouraged to review the labeling of their specific medication and seek guidance from a healthcare professional for personalized advice.
